OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA

OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.